Navigation Links
Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2013

ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  Mr. Riley is scheduled to present at 12:05 p.m. (Eastern Time) on Monday, September 9, 2013 at the Millennium Broadway Hotel in New York City.

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://wsw.com/webcast/rrshq23/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
2. Synthetic Biologics to Report Second Quarter 2013 Financial Results
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. New England Biolabs supports iGEM synthetic biology competition
7. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
8. Intrexon Organizes Around New Synthetic Biology Markets
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
11. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... CA (PRWEB) December 18, 2014 With ... limited time special on Sartorius Biohit products . ... on mLINE pipettes, Picus Electronic Pipette Trade-in Program, and ... Health and Safety officers around the world. They are ... pipetting. Other features include:, ,     Full volume ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 7, 2011 DuPont (NYSE: DD ) ... at the JPMorgan Diversified Industries Conference to expect attractive ... selective investment in attractive areas, broad-based growth, especially in ... also reaffirmed DuPont,s 2011 earnings per share (EPS) outlook ...
... June 7, 2011 Infrared Systems International (OTCBB: IFRS) is ... a pilot study of its NatuRx™ HIV/AIDS treatment and will ... AquaLiv concluded a pilot study with two HIV/AIDS ... anniversary of the first reported AIDS victims on June 5th, ...
... its origins in Hamburg. Jrg Weimller, a materials scientist ... Helmholtz Center Geesthacht, has carried out research on this ... Institute for Metal Research in Shenyang, China., The 51-year-old ... which opens the door to a multitude of diverse ...
Cached Biology Technology:DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3Hard or soft: At the touch of a button 2Hard or soft: At the touch of a button 3
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... fish is good for our brains and memory. But what ... fish, that makes our memory sharper? Medical researchers at ... published their findings in the peer-reviewed journal Applied Physiology, ... his team discovered lab models fed a high-DHA diet had ...
... Steve Moose, an associate professor of maize functional genomics at ... think they may have discovered a new source of heterosis, ... small RNAs (sRNAs), a class of double-stranded RNA molecules that ... refers to the increased vigor or general health, resistance to ...
... the Royal Astronomical Society (RAS) announced a new publishing ... prestigious journals. OUP will assume publication of ... Monthly Notices of the Royal Astronomical Society: Letters , ... Geophysics from January 2013. Professor David Southwood, ...
Cached Biology News:A new source of maize hybrid vigor 2A new source of maize hybrid vigor 3Royal Astronomical Society and Oxford University Press partnership announced 2
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
ANTI S. GROUP AG:H...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: